Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-10-11 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于公司申请向特定对象发行股票的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding a company's application for a non-public issuance of shares to specific investors. It includes extensive information about the use of raised funds, project investment details, and related financial data. The content focuses on capital raising activities, investment projects, and the allocation of proceeds from a specific share issuance. There is no indication that this is an annual report, earnings release, or other types of reports. Instead, it is a detailed disclosure related to a capital raising event and the company's financing plans. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2020-10-11 Chinese
中信证券股份有限公司关于公司向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to Shenzhen BGI Genomics Co., Ltd. issuing shares to specific investors. It is issued by CITIC Securities as the sponsor. The content includes detailed information about the issuance, the sponsor's responsibilities, legal compliance, financial data, shareholder structure, and internal review procedures. The document is a formal sponsorship letter for a specific share issuance, which is a type of capital raising activity. It is not an annual report, earnings release, or a general regulatory filing. It is not a proxy statement or voting result announcement. It is a detailed document related to a financing event, specifically a private placement or non-public issuance of shares. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-11 Chinese
关于公司向特定对象发行股票募集说明书修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding revisions to the prospectus for a private placement of shares (向特定对象发行股票募集说明书修订情况说明的公告). It details updates to the prospectus chapters, including business model, risk factors, and project feasibility, and mentions the updated report period ending June 30, 2020. The document is relatively short (1441 characters) and serves to inform investors about the revised prospectus and where to find it online. It is not the prospectus itself but an announcement about the revision and publication of the fundraising prospectus. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising activities and updates on capital raising documents.
2020-10-11 Chinese
《关于深圳华大基因股份有限公司申请向特定对象发行股票的审核问询函》回复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's response to a regulatory inquiry from the Shenzhen Stock Exchange about a proposed private placement of shares. It mentions the submission of documents and the need for approval from the China Securities Regulatory Commission before implementation. The text does not contain financial statements or detailed financial data but is an update on a capital raising process and regulatory review. The document length is short (803 characters), and it serves as a disclosure announcement related to financing activities. Therefore, it fits best under Capital/Financing Update (CAP).
2020-10-11 Chinese
关于为全资子公司武汉生物科技向银行申请授信提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding a guarantee provided by Shenzhen BGI Genomics Co., Ltd. for its wholly-owned subsidiary Wuhan Biotechnology to obtain bank credit. It details the guarantee amount, terms, and related agreements. The document is relatively short (2019 characters) and focuses on a specific financing guarantee update rather than comprehensive financial data or results. It does not contain financial statements or detailed financial analysis. Therefore, it is an announcement related to capital/financing activities, specifically about a guarantee for financing. This fits best under the category 'Capital/Financing Update (CAP)'.
2020-09-24 Chinese
关于控股子公司产品完成CE认证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding its controlling subsidiary completing CE certification for two nucleic acid test kits. It details product information, market context, and potential impact on the company. The document is relatively short (2188 characters) and does not contain financial statements, detailed financial analysis, or comprehensive report content. It is a regulatory announcement about product certification and market impact, not a financial report or detailed management discussion. There is no indication of it being a full annual report, interim report, earnings release, or other financial filing. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product certification and related business impact without financial data or report content.
2020-09-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.